Collegium Pharmaceutical (NASDAQ:COLL) Price Target Raised to $42.00 at Truist Financial

Collegium Pharmaceutical (NASDAQ:COLL) had its price target upped by equities research analysts at Truist Financial from $40.00 to $42.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Truist Financial’s price target would suggest a potential upside of 19.15% from the company’s previous close.

Several other equities analysts also recently weighed in on COLL. Jefferies Financial Group upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and lifted their target price for the stock from $41.00 to $44.00 in a research note on Friday, June 7th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. HC Wainwright upgraded shares of Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Tuesday, July 30th. Finally, Piper Sandler restated a “neutral” rating and issued a $37.00 price objective (down from $39.00) on shares of Collegium Pharmaceutical in a research report on Friday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL traded down $0.07 during trading hours on Friday, reaching $35.25. 59,890 shares of the company were exchanged, compared to its average volume of 468,716. Collegium Pharmaceutical has a 1 year low of $20.95 and a 1 year high of $40.95. The business’s 50 day simple moving average is $32.99 and its 200-day simple moving average is $34.81. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98. The stock has a market capitalization of $1.15 billion, a P/E ratio of 14.49 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.04). The business had revenue of $144.92 million during the quarter, compared to analysts’ expectations of $147.04 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. On average, equities research analysts expect that Collegium Pharmaceutical will post 5.73 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, Director Garen G. Bohlin sold 28,985 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total value of $936,215.50. Following the completion of the sale, the director now directly owns 44,775 shares in the company, valued at approximately $1,446,232.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Garen G. Bohlin sold 28,985 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total value of $936,215.50. Following the transaction, the director now directly owns 44,775 shares of the company’s stock, valued at $1,446,232.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Scott Dreyer sold 56,807 shares of Collegium Pharmaceutical stock in a transaction on Friday, May 24th. The stock was sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the completion of the transaction, the executive vice president now directly owns 105,902 shares in the company, valued at $3,598,549.96. The disclosure for this sale can be found here. Insiders sold a total of 105,502 shares of company stock worth $3,540,796 over the last three months. 3.98% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Collegium Pharmaceutical by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock worth $90,479,000 after buying an additional 17,942 shares during the period. Principal Financial Group Inc. increased its position in Collegium Pharmaceutical by 8.2% during the 2nd quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock valued at $54,124,000 after purchasing an additional 128,003 shares during the period. Dimensional Fund Advisors LP increased its position in Collegium Pharmaceutical by 2.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,039,218 shares of the specialty pharmaceutical company’s stock valued at $31,987,000 after purchasing an additional 29,529 shares during the period. Emerald Mutual Fund Advisers Trust increased its position in Collegium Pharmaceutical by 3.8% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 530,456 shares of the specialty pharmaceutical company’s stock valued at $17,081,000 after purchasing an additional 19,255 shares during the period. Finally, LSV Asset Management increased its position in Collegium Pharmaceutical by 188.7% during the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after purchasing an additional 248,751 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.